The retatrutide trial record: Phase 1 through Phase 2, mechanism through outcomes.

The short version

Retatrutide is a 39-amino-acid investigational peptide that activates three hormone receptors at once — GLP-1, GIP, and glucagon. No approved drug does all three simultaneously. The combination is why the trial numbers are larger than prior single- or dual-receptor approaches.

The published record spans a first-in-human Phase 1b study, two Phase 2 trials (obesity and type 2 diabetes), a Phase 2a MASLD (fatty liver disease) substudy, and structural biology work confirming triple-receptor engagement. Phase 3 trials — the TRIUMPH program — are ongoing.

The main efficacy findings: -24.2% body weight at 48 weeks (obesity); -2.02% HbA1c and -16.94% body weight at 36 weeks (type 2 diabetes); -82.4% liver fat at 24 weeks (MASLD). The main safety signals: dose-related GI adverse events, dose-dependent heart-rate increase, and unknown long-term cardiovascular and kidney outcomes. This page lays out the evidence structure behind those numbers.

Mechanism: triple-receptor pharmacology

Retatrutide is a synthetic GIP-backbone peptide acylated with a C20 fatty-diacid chain for albumin binding and extended half-life. It is a simultaneous agonist at three class-B G-protein-coupled receptors (GPCRs — a family of cell-surface receptors that relay hormone signals into the cell).

The GLP-1 receptor (GLP-1R) arm suppresses appetite via central nervous system satiety signaling and slows gastric emptying. The GIPR arm augments glucose-dependent insulin secretion and modulates adipose tissue metabolism. The glucagon receptor (GCGR) arm increases energy expenditure and accelerates hepatic (liver) lipid metabolism through cAMP/PKA downstream signaling. The glucagon contribution is the key mechanistic addition over approved dual GIP/GLP-1 agents: it adds energy expenditure and hepatic lipid clearance without the hyperglycemia risk of pure glucagon, because GLP-1 simultaneously augments insulin.

Cryo-EM structures (a technique for imaging molecular structures at near-atomic resolution) published in 2024 resolved retatrutide binding to all three receptors, confirming simultaneous triple engagement. Relative potency compared to native hormones: 8.9 times at GIPR, 0.3 times at GCGR, and 0.4 times at GLP-1R ^[3]. The GIPR super-agonism and attenuated GCGR agonism are deliberate engineering choices — enough glucagon effect for metabolic benefit, not enough to acutely raise blood glucose.

For a dedicated mechanistic page, see how does retatrutide work.

Phase 1b: first-in-human pharmacokinetics

The first-in-human Phase 1b trial enrolled 72 adults with type 2 diabetes and HbA1c between 7.0 and 10.5%. Participants received once-weekly subcutaneous injections at 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg over 12 weeks. Key pharmacokinetic finding: half-life approximately 6 days, consistent with once-weekly dosing ^[4].

The highest-dose group lost 8.96 kg placebo-adjusted (90% confidence interval: -11.16 to -6.75) over 12 weeks. Daily glucose fell by 2.8 mmol/L at 3 mg. Treatment-emergent adverse events in 63% of participants, mostly gastrointestinal. Safety profile assessed as acceptable by the investigators ^[4].

The 6-day half-life derives from the C20 fatty-diacid acylation that enables albumin binding in plasma — the same pharmacokinetic engineering used to extend half-life in related incretin agents.

Phase 2: obesity trial (48 weeks)

The pivotal Phase 2 obesity trial enrolled 338 adults with BMI >=30, or 27 to <30 with a weight-related comorbidity; 51.8% male. Participants were randomized to 1, 4, 8, or 12 mg once weekly or placebo, with dose escalation, for 48 weeks ^[1].

Mean body-weight change at 48 weeks: -8.7%, -17.3%, -22.8%, -24.2% (doses 1, 4, 8, 12 mg) versus -2.1% placebo. The dose-response was monotonic across all four active arms. Gastrointestinal adverse events were dose-related and mostly mild to moderate. A dose-dependent increase in resting heart rate was observed, peaking around week 24. Discontinuation rate at the highest dose was 18%, principally GI-driven ^[1].

A 2025 systematic review and network analysis across 26 RCTs (15,491 participants without diabetes) found retatrutide 12 mg produced the largest weight-loss estimate at 48 weeks among agents reviewed: 22.1% (95% CI 19.3%–24.9%), ahead of tirzepatide 15 mg (up to 17.8% at 72 weeks) and semaglutide 2.4 mg (up to 13.9% at 68 weeks). The comparison is descriptive — no head-to-head trials existed and cross-trial heterogeneity prevented pooled meta-analysis ^[9].

Retatrutide vs tirzepatide

No head-to-head trial of retatrutide versus tirzepatide has been published. The comparison in the published literature is cross-trial and descriptive: retatrutide's Phase 2 weight-loss figure (-24.2%) exceeds tirzepatide's Phase 2 figure in non-diabetic adults (-20.9% at the 15 mg dose in the SURMOUNT-1 trial) over comparable durations. Eli Lilly has registered a Phase 3 TRIUMPH trial that includes an active-comparator arm against tirzepatide, but results have not been published. The mechanistic difference is the glucagon receptor addition: tirzepatide is a dual GLP-1/GIP agonist; retatrutide adds the GCGR arm and its energy-expenditure and hepatic-lipid effects.

Phase 2: type 2 diabetes trial (36 weeks)

281 adults with type 2 diabetes were enrolled and randomized to dose-escalating regimens from 0.5 to 12 mg once weekly or placebo, or an active comparator, for 36 weeks ^[2].

At the 12 mg dose at 24 weeks: HbA1c -2.02% versus -0.01% with placebo. Body-weight change at 36 weeks: -16.94% versus -3.00% placebo. Mild to moderate GI adverse events in 35% of participants. No severe hypoglycemia, no deaths recorded. A 2026 overview of the full diabetes efficacy data reported HbA1c reduction up to 2.16% and weight loss up to 26.56% across the studied populations, with GI events linked to escalation rate and starting dose ^[12].

Phase 2a: MASLD liver-fat substudy

This is the study this site's lens is built around. Ninety-eight participants with obesity or overweight and MASLD (liver fat >=10% on MRI-PDFF, no type 2 diabetes) were randomized to 1, 4, 8, or 12 mg once weekly or placebo for 48 weeks ^[5].

Relative liver-fat change at 24 weeks: -42.9%, -57.0%, -81.4%, -82.4% (1, 4, 8, 12 mg) versus +0.3% with placebo. Normal liver fat (<5%) was reached by 86% of the 12 mg group at 24 weeks. By 48 weeks: -86.0% at 12 mg.

This is the signal that puts retatrutide at the top of any published comparison for liver-fat reduction. A systematic review of double-blind RCTs confirmed the 81% placebo-subtracted MRI-PDFF reduction for retatrutide was the largest among agents reviewed — semaglutide 41%, tirzepatide 47% ^[7]. A meta-analysis of 25 RCTs (2,600 patients) across GLP-1-based therapies found retatrutide displaying the most pronounced liver-fat reduction, with significant reductions in ALT, AST, and GGT (liver-enzyme markers of hepatic stress) ^[8].

A 2025 mouse model study confirmed retatrutide significantly reduced ALT, hepatic triglycerides, hepatic cholesterol, and inflammatory markers in accelerated diet-induced steatohepatitis, with a hepatic gene expression profile that correlated with human MASH ^[13]. A 2026 review of MASLD treatment in the context of type 2 diabetes characterized retatrutide as showing marked liver-fat reduction with MASH benefit signals ^[15].

2024-2025 publications: recent findings

Cryo-EM structural biology (Cell Discovery, 2024). Li W et al. resolved triple-agonist binding at 2.68/3.26/2.84 angstroms at GLP-1R, GIPR, and GCGR respectively — the first structural confirmation of simultaneous triple engagement. The extracellular loop 1 (ECL1) adopts a rigid alpha-helix at GLP-1R and GCGR but a flexible loop at GIPR, a structural distinction that may explain the receptor-selectivity engineering ^[3].

Weight-loss blockbusters review (Annual Review, 2025). Zhou Q et al. identified weight rebound after treatment cessation as a class-level challenge for retatrutide and related multi-receptor agonists. Durability beyond the Phase 2 trial windows remains uncharacterized ^[10].

GLP-1 efficacy and safety review (Diabetes Care, 2024). Drucker DJ et al. characterized retatrutide among investigational molecules with unique pharmacokinetic and pharmacodynamic profiles via triple receptor activation, distinguishing it from first-generation GLP-1 receptor agonists ^[11].

Resistant and refractory obesity review (IJMS, 2026). Nicze M et al. identified post-treatment weight regain as one of three failure modes in anti-obesity pharmacotherapy, noting that identifying pretreatment predictors enables personalized management ^[14].

Retatrutide overview (Expert Review, 2026). Panou T et al. synthesized efficacy across the full Phase 1/2 dataset and linked GI adverse events to escalation rate and starting dose — providing a practical framework for trial-design interpretation ^[12].

Retatrutide research: open questions

The Phase 2 record is substantial. What is not yet documented:

Long-term cardiovascular outcomes. The TRIUMPH cardiovascular outcomes trial (NCT06383390) is ongoing — no results. The dose-dependent heart-rate increase observed in Phase 2 raises questions about arrhythmia burden and MACE at scale that Phase 2 was not powered to answer.

Kidney safety at scale. The TRANSCEND-CKD trial (NCT05882045) is specifically studying renal effects. Phase 2 did not enroll participants with advanced CKD, leaving this population uncharacterized.

Durability after discontinuation. Data from analogous GLP-1 class agents consistently show substantial weight rebound after stopping treatment. No published retatrutide discontinuation data exist.

Long-term lean-mass outcomes. The 2025 body-composition substudy confirmed absolute lean-mass reduction in Phase 2. Whether resistance training protocols and protein intake sufficiently mitigate this at scale is an open design question for Phase 3.

For the Retatrutide references that underpin this reading, see the sources page.